| Ytd | 20.18% | |
| 1y | 547.17% |
| Open | 94.00 | Prev Close | 94.75 | Low | 92.50 | High | 103.79 | Mkt Cap | 1.39B |
| Vol | 296.67K | Avg Vol | 450.54K | EPS | -8.39 | P/E | N/A | Forward P/E | -15.04 |
| Beta | 3.32 | Short Ratio | 9.81 | Inst. Own | 83.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 106.69 | 200-d Avg | 77.72 | 1yr Est | 277.50 |
INBX News
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027If Approved, Oz
Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.15) per share which missed the an
Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response r
Today, the Company presented preliminary data from 53 patients (25 in the INBRX-106 combination arm
– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewsw
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding
U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares
US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69
https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-s
Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) in the second half of 2026 to
Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrad
Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy ratin
Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading streng
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company anno
Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 422 stocks made new 52-week lows.
During the Thursday's session, 100 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched
Gainers
Gainers
Friday's session saw 466 companies set new 52-week highs.
During Thursday's morning session, 316 companies made new 52-week highs.
On Tuesday morning, 113 companies hit new 52-week highs.